Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Healthcare Industry News Hempsana to manufacture Cream of the Crop Terpene Rich Relief Cream Hempsana Holdings said that it has forged a custom manufacturing deal with Cream of the Crop Therapeutics to… byPallavi MadhirajuNovember 27, 2021